Pancreatic safety of DPP-4 inhibitors in type 2 diabetes millitus: A protocol for systematic review and network

Related Experiment Video

Updated: Sep 24, 2025

High Resolution 3D Imaging of the Human Pancreas Neuro-insular Network
09:54

High Resolution 3D Imaging of the Human Pancreas Neuro-insular Network

Published on: January 29, 2018

11.2K

Fan Yang1, Youzi Dong1, Baohua Li1

  • 1The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.

Medicine
|May 5, 2022
PubMed
Abstract

Insights

This review assesses the pancreatic safety of dipeptidyl-peptidase IV inhibitors (DPP-4i) for type 2 diabetes. Findings will aid clinical decisions regarding these common hypoglycemic drugs.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Clinical Research

Background:

  • Dipeptidyl-peptidase IV inhibitors (DPP-4i) are widely used for type 2 diabetes due to efficacy and low risk of hypoglycemia/weight gain.
  • Concerns exist regarding the pancreatic safety of DPP-4i, but clinical evidence is limited.
  • Existing evidence on DPP-4i pancreatic safety is insufficient, necessitating further investigation.

Purpose of the Study:

  • To systematically evaluate the pancreatic safety of DPP-4 inhibitors in patients with type 2 diabetes mellitus.
  • To conduct a pairwise and network meta-analysis to synthesize available evidence.
  • To provide evidence-based information to support clinical decision-making.

Main Methods:

  • Comprehensive literature search across major databases (MEDLINE, Embase, PubMed, Web of Science, Cochrane).
  • Inclusion of published and unpublished trials, with rigorous screening and data extraction by two independent reviewers.
  • Risk of bias assessment using the Cochrane tool and evidence quality interpretation via the GRADE approach; statistical analysis using STATA and WinBUGS.

Main Results:

  • This study will evaluate the pancreatic safety of DPP-4 inhibitors in type 2 diabetes mellitus.
  • Results will synthesize data from eligible studies to assess pancreatic safety outcomes.
  • The analysis aims to identify any potential risks associated with DPP-4i use.

Conclusions:

  • This systematic review and network meta-analysis will provide a comprehensive evaluation of DPP-4i pancreatic safety in type 2 diabetes.
  • Findings are expected to supplement existing evidence, enhance understanding, and guide treatment decisions.
  • The study aims to improve patient and clinician awareness regarding DPP-4i pancreatic safety.

More Related Videos

Isolation of Human Islets from Partially Pancreatectomized Patients11:10

Isolation of Human Islets from Partially Pancreatectomized Patients

Published on: July 30, 2011

16.4K
Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise05:06

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise

Published on: July 14, 2023

1.9K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
272
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
449
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
318
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
280
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
12.0K